Abbott Slashes HIV Drug Price For Developing Nations

Law360, New York (August 15, 2006, 12:00 AM EDT) -- Still struggling with how to protect its patent rights, drug maker Abbott Laboratories Inc. has said it will launch new initiatives aimed at expanding the availability of its new HIV medicine in the developing world.

Abbott said it plans to make its lopinavir/ritonavir tablet—marketed under as Kaletra in developed markets and as Aluvia in developing nations—available to 45 low and middle-income nations at a significantly reduced price.

The drug maker already supplies the medicine to 69 African and "least developed countries" for $500 a year per...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.